[225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in challenging advanced mCRPC patients

被引：0
|
作者：
Rosar, F. [1 ]
Krause, J. [1 ]
Bartholomae, M. [1 ]
Maus, S. [1 ]
Stemler, T. [1 ]
Hierlmeier, I. [1 ]
Linxweiler, J. [2 ]
Ezziddin, S. [1 ]
Khreish, F. [1 ]
机构：
[1] Saarland Univ, Dept Nucl Med, Med Ctr, Homburg, Germany
[2] Saarland Univ, Dept Urol, Med Ctr, Homburg, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0901
引用
下载
收藏
页码：S315 / S315
页数：1
相关论文
共 50 条
  • [41] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [42] 225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand TherapyPilot Experience From a Prospective Registry
    Rosar, Florian
    Burgard, Caroline
    Rohloff, Luna Vanessa
    Blickle, Arne
    Bartholomae, Mark
    Maus, Stephan
    Petto, Sven
    Schaefer-Schuler, Andrea
    Ezziddin, Samer
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : 621 - 629
  • [43] [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617
    Busslinger, Sarah D.
    Tschan, Viviane J.
    Richard, Olivia K.
    Talip, Zeynep
    Schibli, Roger
    Mueller, Cristina
    CANCERS, 2022, 14 (22)
  • [44] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [45] Preparation of Patient Doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) 177Lu
    Raviteja Nanabala
    Maroor Raghavan Ambikalmajan Pillai
    Buvaneswari Gopal
    Nuclear Medicine and Molecular Imaging, 2022, 56 : 313 - 322
  • [46] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [47] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [48] Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617
    Martin, Sebastian
    Tonnesmann, Roswitha
    Hierlmeier, Ina
    Maus, Stephan
    Rosar, Florian
    Ruf, Juri
    Holland, Jason P.
    Ezziddin, Samer
    Bartholoma, Mark D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) : 4960 - 4971
  • [49] Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
    Tauber, R. L.
    Feuerecker, B.
    Knorr, K.
    Beheshti, A.
    Seidl, C.
    D'Alessandria, C.
    Bruchertseifer, F.
    Retz, M.
    Gschwend, J. E.
    Weber, W.
    Morgenstern, A.
    Eiber, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
12345